Asia
Extrawell Pharmaceutical Expects Swing to Loss in Fiscal 2026
Extrawell Pharmaceutical (HKG:0858) expects to post a loss of at least HK$950 million for fiscal 2026, compared with a profit in fiscal 2025, according to a Tuesday Hong Kong bourse filing.The company attributed the expected swing to an unrealized loss on its investment in convertible bonds issued by Starcoin Group (HKG:0399), whose shares were suspended from trading in May, as well as impairment provisions on its interest in an associate and related loan receivables.
HKG:0399HKG:0858
